At the time of writing, Acelyrin Inc [SLRN] stock is trading at $8.34, up 2.21%. An important factor to consider is whether the stock is rising or falling in short-term value. The SLRN shares have gain 9.16% over the last week, with a monthly amount glided 16.64%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 15, February 2024, ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications. In a post published today on Yahoo Finance, Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies.
From an analyst’s perspective:
Acelyrin Inc [NASDAQ: SLRN] stock has seen the most recent analyst activity on December 13, 2023, when Wells Fargo initiated its Equal Weight rating and assigned the stock a price target of $11. Previously, Citigroup started tracking the stock with Neutral rating on December 08, 2023, and set its price target to $8. On September 13, 2023, downgrade downgraded it’s rating to Equal-Weight but maintained its price target of $19 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $44 on September 05, 2023. TD Cowen initiated its recommendation with a Outperform. Piper Sandler started tracking with a Overweight rating for this stock on May 30, 2023, and assigned it a price target of $68. In a note dated May 30, 2023, Morgan Stanley initiated an Overweight rating.
For the past year, the stock price of Acelyrin Inc fluctuated between $5.70 and $29.88. Acelyrin Inc [NASDAQ: SLRN] shares were valued at $8.34 at the most recent close of the market.
Analyzing the SLRN fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.12 points at the first support level, and at 7.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.55, and for the 2nd resistance point, it is at 8.75.
Acelyrin Inc [SLRN] reported earnings per share of -$0.87 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.5/share, meaning a difference of -$0.37 and a surprise factor of -74.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.4 per share as compared to estimates of -$0.76 per share, a difference of $0.36 representing a surprise of 47.40%.
Ratios To Look Out For
It is important to note that Acelyrin Inc [NASDAQ:SLRN] has a current ratio of 11.88. On the other hand, the Quick Ratio is 11.88, and the Cash Ratio is 0.05.
Transactions by insiders
Recent insider trading involved Lin Shao-Lee, Chief Executive Officer, that happened on Feb 20 when 15701.0 shares were sold. Chief Executive Officer, Lin Shao-Lee completed a deal on Jan 02 to sell 10691.0 shares. Meanwhile, 10% Owner Westlake BioPartners Fund II, bought 1.25 million shares on May 09.
